The Department of Defense is offering the Peer Reviewed Alzheimer’s Convergence Science Research Award (PRARP) FY15 to support researchers in generating resources and tools for health sciences related to Alzheimer’s and Traumatic Brain Injury (TBI). Applicants are required to address challenges such as the paucity of research resources and diagnostic technologies to detect the progression of Alzheimer’s following TBI. Focus areas include genomics, pathology of Tau, roles of non-neuronal cells in TBI/AD pathogenesis, and novel target identification. Pharmacologic interventions are discouraged. This grant aims to benefit military, Veteran, and civilian communities by advancing research in Alzheimer’s disease. Deadline: Nov 25, 2015.
Opportunity ID: 277963
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-15-PRARP-CSRA |
| Funding Opportunity Title: | DoD FY15 Peer Reviewed Alzheimer’s Convergence Science Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 4 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 20, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Nov 25, 2015 |
| Current Closing Date for Applications: | Nov 25, 2015 |
| Archive Date: | Dec 25, 2015 |
| Estimated Total Program Funding: | $2,800,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The Peer Reviewed Alzheimer’s Research Program (PRARP) Convergence Science Research Award (CSRA) mechanism was first offered in FY12. Since then, 92 CSRA applications have been received, and 22 have been recommended for funding. The intent of the FY15 CSRA is to support efforts to generate research resources, tools, or novel research efforts for researchers and/or practitioners in health sciences related to the PRARP’s mission. The research impact will benefit the military, Veteran, and civilian communities. The CSRA is open to Principal Investigators (PIs) at or above the level of Assistant Professor (or equivalent) from any field or discipline who seek to bring their expertise to address the PRARP’s mission. However, as part of the application, the PI should demonstrate that the study team has experience in both TBI and AD research. Preliminary data, while not required, is encouraged. FY15 CSRA Overarching Challenges: This CSRA funding opportunity requires applications to address one or more of the following Overarching Challenges: Paucity of Research Resources: The paucity of research resources to examine the interrelationship between TBI and subsequent AD for the military and Veteran communities. Paucity of Clinical Studies: The paucity of clinical or epidemiological studies to examine the interrelationship between TBI and subsequent AD for the military and Veteran communities. Diagnostic Technologies, Tests, or Devices: The need for technologies, tests, or devices to detect the progression to AD subsequent to TBI. FY15 CSRA Focus Areas: In addition to addressing one or more of the specified FY15 Overarching Challenges, applications should also address at least one of the following FY15 Focus Areas in support of the FY15 Overarching Challenges. An application that proposes research outside of the FY15 Focus Areas is acceptable, as long as the applicant provides a strong rationale. Genomics/Proteomics/Bioinformatics: Studies or technologies (e.g., genetic, proteomic, and epigenetic strategies) intended to characterize neurological change(s) associated with TBI and subsequent AD. In addition, relevant technologies or tests may be considered under this focus area. Pathology of Tau: Novel research and technologies dedicated to unraveling the basic pathological mechanisms of Tau associated with TBI and AD. Roles of Non-Neuronal Cells in TBI/AD Pathogenesis: Technologies, tests, studies, or devices that will examine the roles of astrocytes (or other non-neuronal cells) in AD neurodegeneration due to TBI. Novel Target Identification: Basic research (non-human) directly leading to the identification of new targets for the development of existing or new investigational medicines, drugs, or agents. The following is specifically discouraged under the FY15 PRARP: Pharmacologic Interventions: Clinical or Basic research requiring investigational or U.S. Food and Drug Administration (FDA)-approved drugs or medicines. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 277963 Full Announcement-1 -> w81xwh-15-prarp-csra.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00217896 | Jul 20, 2015 | Nov 25, 2015 | View |
Package 1
Mandatory forms
277963 RR_SF424_2_0-2.0.pdf
277963 RR_Budget_1_3-1.3.pdf
277963 RR_KeyPersonExpanded_2_0-2.0.pdf
277963 PerformanceSite_2_0-2.0.pdf
Optional forms
277963 RR_SubawardBudget30_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
